1. Мосолов С.Н., Костюкова Е.Г., Кузавкова М.В. Биполярное аффективное расстройство: диагностика и терапия/под редакцией С.Н. Мосолова М.: МЕДпресс-информ, 2008. - с. 15

2. Grunze H., Vieta E., Goodwin GM., Bowden C., Licht R.W., H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.//World J Biol Psychiatry. - 2010. - N 11. - p. 81 - 109

3. McDonald K.C., Bulloch A.G.M., Duffy A., et al. Prevalence of bipolar I and II disorder in Canada//Can J Psychiatry. - 2015; N. 60 P. 151 - 6.

4. Bauer M., Glenn T., Alda M., et al. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder//Eur Psychiatry. - 2015; N. 30 P. 99 - 105.

5. Hwu H.G., Yeh E.K., Chang L.Y. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule//Acta Psychiatr Scand. - 1989 N. 79 P. 136 - 147.

6. Wittchen H.U., Essau C.A., von Zerssen D., Krieg J.C., Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study//Eur Arch Psychiatry Clin Neurosci. - 1992 N. 241 P. 247 - 258.

7. Hirschfeld R.M.A., Calabrese J.R., Weissman M., et al. Lifetime prevalence of bipolar I and II disorders in the United States [abstract]//Presented at the 155^th American Psychiatric Association Annual Meeting, - 2002, May 18 - 23, Philadelphia, PA, USA

8. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DMS-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. - 1994, N. 51 P. 18 - 19.

9. Angst J., Gamma A., Benazzi F., Ajdacic V., Eich D., W. Diagnostic issues in bipolar disorder//Europ. Neuropsychopharm. - 2003. - Vol. 13. - S43 - S50.

10. Angst J., Stassen H.H., Clayton P.J. et al. Mortality of patients with mood disorders: follow up over 34 - 38 years//J. Affect. Disord. - 2002. - Vol. 68. - p. 167 - 181

11. Licht R.W., Vestergaard P., Brodersen A. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord. - 2008, N. 10. P. 79 - 86.

12. Беляев Б.С. Клиническая дифференциация и систематика эндогенных аффективных психозов//Журнал невропатологии и психиатрии. - 1991. - Т. 91. - No 12. - С. 51 - 55.

13. Психиатрическая помощь населению Российской Федерации в 2015 - 2017 гг. Аналитический обзор под ред. З.И. Кекелидзе. ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России, М., - 2018, с. 142

14. Lish J.D., Dime-Meenan S., Whybrow P.C., et al. The national Depressive and Manic-Depressive Association (DMDA) survey of bipolar members//J. Affect Disord., - 1994; N. 31. P. 281 - 294.

15. Hirschfeld R.M., Lewis L., Vornik L.A. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder//J Clin Psychiatry. - 2003. - Vol. 64. - P. 161 - 174.

16. Международная классификация болезней (10 пересмотр). Всемирная организация здравоохранения. Перевод на русский язык под ред. Нуллер Ю.Л., Циркин С.Ю.//Россия. С-П "Оверлайд", 1994.

17. Мосолов С.Н., Ушкалова А.В., Костюкова Е.Г., Шафаренко А.А., Алфимов П.В., Костюкова А.Б. Диагностика биполярного аффективного расстройства II типа среди пациентов с текущим диагнозом рекуррентного депрессивного расстройства//Современная терапия психических расстройств. - 2014. - Вып. 2. - С. 2 - 14

18. Мосолов С.Н., Шафаренко А.А., Ушкалова А.В., Алфимов П.В., Костюкова А.Б. Формализованная диагностика биполярного аффективного расстройства у больных с приступообразной шизофренией и шизоаффективным расстройством//Современная терапия психических расстройств. - 2014. - Вып. 3. - С. 2 - 8

19. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric. J Clin Psychiatry 78:8, September/October 2017 1100

20. Мосолов С.Н. Основы психофармакотерапии//Восток. - 1996. - 374 с.

21. Мосолов С.Н., Костюкова Е.Г. Клинические рекомендации по терапии быстроциклического течения биполярного расстройства//Современная терапия психических расстройств. - 2008. - N 1. - С. 38 - 46.

22. Мосолов С.Н. Обрыв континуального течения аффективных колебаний с помощью карбамазепина и вальпроата натрия у резистентных к лечению солями лития больных эндогенными психозами//Психопатологические и патогенетические аспекты прогноза и терапии депрессии. - М., 1986. - С. 75 - 80

23. Мосолов С.Н., Мощевитин.С.Ю. Применение электросудорожной терапии для обрыва континуального течения терапевтически резистентных аффективного и шизоаффективного психозов. Ж-л Невропатологии и психиатрии им. С.С. Корсакова, 1990, 4, с. 121 - 125

24. Bauer M.S., Calabrese J.R., Dunner D.L., et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV//Am J Psychiatry. - 1999. N. 151 P. 506 - 515.

25. Dunner D., Patrick V., Fieve R. Rapid cycling manic-depressive patients//Comprehensive Psychiat., - 1977, Vol. 18, N 6, p. 561 - 566.

26. Suppes T., Leverich G.S., Keck P.E. et al. The Stanley Foundation Bipolar treatment outcome Network II. Demographics and illness characteristics of the first 261 patients//J. Affect. Disorder, - 2001. N. 67 P. 45 - 59.

27. Wehr T.A., Sack D.A. et al., Rapid cycling affective disorder contributing factors and treatment responses in 51 patients. Am J Psychiatry. - 1988. - N 145. - p 179 - 184

28. Костюкова Е.Г., Мосолов С.Н. Современная диагностика и терапия биполярного аффективного расстройства: от доказательных научных исследований к клинической практике.//Биологические методы терапии психических расстройств (доказательная медицина - клинической практике) под. Редакцией С.Н. Мосолова. Москва, 2012, стр. 491 - 529

29. Kogan J.N., Otto M.W., Bauer M.S. et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)//Biol Psychiatry, - 2004.

30. Frye M.A., Altshuler L.L., McElroy S.L. et al. Gender differences in prevalence, risk and clinical correlate of alcoholism comorbidity in bipolar disorder//Am. J. Psychiatry, 2003, Vol. 160, p. 883 - 889.

31. Kupfer D.J., Frank E. Trends in diagnosis and treatment of bipolar disorders//Medicographia, - 2005. N. 27 P. 254 - 260.

32. Мосолов С.Н., Костюкова Е.Г. Биполярное аффективное расстройство//Национальное руководство. Психиатрия под ред. Александровский Ю.А., Незнанов Н.Г. - Геотар Медиа. - 2018 - с. 704 - 799

33. Angst J, Gamma A, Bowden CL, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes//Eur Arch Psychiatry Clin Neurosci. - 2012; N. 262. P. 3 - 1

34. Angst J., Adolfsson R., Benazzi F. et al. The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatients//J Affect Dis. - 2005. - Vol. 88, No 22. - P. 217 - 233.

35. Мосолов С.Н., Ушкалова А.В., Костюкова Е.Г., Шафаренко А.А., Алфимов П.В., Костюкова А.Б., Курсаков А.А., Образцова Л.В. Валидизация российской версии опросника HCL-32 для выявления пациентов с биполярным аффективным расстройством II типа среди больных, наблюдающихся с диагнозом рекуррентного депрессивного расстройства//Социальная и клиническая психиатрия. - 2015. - Т. 25, Вып. 1. - С. 22 - 30.

36. Truman C.J., Goldberg J.F., Ghaemi S.N., Baldassano C.F., Wisniewki S.R., Dennehy E.B., Thase M.E., Sachs G.S. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)//J Clin Psychiatry. - 2007. N. 68 P. 1472 - 1479

37. Yatham L., Kennedy S., Parikh S. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder//Bipolar Disorders. - 2018. P. 1 - 74.

38. Posner K., Oquendo M.A., Gould M., Stanley B., Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA's Pediatric Suicidal Risk Analysis of Antidepressants//Am J Psychiatry, 200; 164: 1035 - 1043.

39. Dong M. et al. Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies//Epidemiology and Psychiatric Sciences. - 2019. P. 1 - 9.

40. Grunze H., Vieta E., Goodwin G.M. et al. The World Federation of Societies of Biological Psychiatry (WFSBP] Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder//World J Biol Psychiatry. - 2013. - Vol. 14. - P. 154 - 219

41. Ogawa Y., Tajika A., Takeshima N., Hayasaka Y., Furukawa T.A. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy//CNS Drugs. - 2014. N. 28. P. 989 - 1003.

42. Cipriani A., Barbui C., Salanti G., Rendell J., Brown R., Stockton S., et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis//Lancet. - 2011. N. 378 P. 1306 - 1315.

43. Мосолов С.Н., Костюкова Е.Г., Кузавкова М.В. Профилактическое применение антиконвульсантов при фазнопротекающих эндогенных психозах (сравнительное изучение карбамазепина, вальпроата натрия и солей лития). В кн. Антиконвульсанты в психиатрической и неврологической практике. Под ред. Вейн А.М., Мосолов С.Н. Медицинское информационное агентство, С-П, 1994, с 72 - 128

44. Шафаренко А.А., Мосолов С.Н. Современная терапия маниакальных и маниакально-бредовых состояний: от доказательных научных исследований к клиническим рекомендациям//Биологические методы терапии психических расстройств: доказательная медицина - клинической практике/Под ред. С.Н. Мосолова. - М., 2012. - с. 554 - 585.

45. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N.R., Daniel D et al. Olanzapine versus placebo in the treatment of acute mania.//American J. of Psychiatry, 1999; N 156; P. 702 - 709

46. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G. et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study.//Archives of General Psychiatry. - 2000. - N 57. - P. 841 - 849

47. Tohen M., Zhang F., Taylor S., Burns P., Zarate C., Sanger T. A meta-analysis of the use of typical antipsychotics agents in bipolar disorder.//J. Affect. Disord. - 2001. - N 65. - P. 85 - 93

48. Tohen M., Baker R.W., Altshuler L.L., Zarate C.A., Supps T., Ketter T.A. et al. Olanzapine versus divalproex in the treatment of acute mania.//American J. of Psychiatry. - 2002. - N 159. - P. 1011 - 1017

49. Brecher M., Huizar K. Quetiapine vs placebo for acute mania associated with bipolar disorder.//Bipolar Disorders. - 2003. - V. 5. - Sappl 1, P. 35

50. Jones M., Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder.//Bipolar Disorders. - 2003. - V. 5. - Suppl 1. - P. 57

51. Segal J., Berk M., Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.//Clin. Neuropharmacol. - 1998. - N 21. - P. 176 - 180.

52. Segal S., Reisenberg R., Ice K., English P. Ziprasidone in mania: A 21-day randomized, double blind, placebo controlled trial.//Eur. Neuropsychopharmacol. - 2003. - N 13. - (Suppl. 4). - P. 345.

53. Keck PE, Ice K. A 3-week double blind randomized trial of ziprasidone in acute treatment of mania//Eur Neuropsychopharmacol. - 2000. - 10 (suppl. 3). - S. 297

54. Keck P., Versiani M., Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, double-blind, placebo-controlled randomized trial.//Am. J. Psychiatry, 2003. - N 160. - 741 - 748

55. Bourin M. Aripiprazole: a view point by H. Bourin//CNS Drugs. - 2004. - Vol. 18. - N 6. - p. 377 - 378

56. Мосолов С.Н. Дифференцированная терапия маниакальных, маниакально-бредовых и маниакально-гебефренных состояний при эндогенных психозах: автореф. дисс. ... канд. мед. наук. - М., 1983. - 21 с.

57. Emrich H.M., Dose M., Von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders//J Affect Disord. - 1985. - No 8. - P. 243 - 250.

58. Bowden C.L. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects.//J. Clin. Psychiatry, - 1998; V. 59, Suppl 6, P. 13 - 19, discussion 20.

59. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G., Chou J.C., Keck P.E., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group//Arch Gen Psychiatry. - 2000. - Vol. 57. - P. 481 - 489.

60. Bowden C.L., Mosolov S., Hranov L., Chen E., Habil H., Kongsakon R., Manfredi R., Lin H. N Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial//International Clinical Psychopharmacology. 2010. - V. 25. - No 2. p. 60 - 67

61. Gelenberg A.J., Kane J.M., Keller M.B. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders.//N. Engl. J. Med-. - 1989-. - Vol. 321-. - P. 1489 - 1493

62. Цукарзи Э.Э. Неотложная помощь при агрессивном поведении. Часть II. Ведение пациентов//Ж. Современная терапия психических расстройств., - 2013, N 2, с. 31 - 40

63. Gaynes B.N., Brown C., Lux L.J., et al. Strategies to De-escalate Aggressive Behavior in Psychiatric Patients. AHRQ Comparative Effectiveness Reviews. Report no. 16-EHC032-EF. 2016, Rockville, MD: Agency for Healthcare Research and Quality.

64. Putkonen A., Kuivalainen S., Louheranta O., et al. Cluster-randomized controlled trial of reducing seclusion and restraint in secured care of men with schizophrenia//Psychiatr Serv. - 2013, N. 64 P. 850 - 855.

65. Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study//Neuropsychobiology, 2010, 62: 81 - 86.

66. Simpson J.R., Thompson C.R., Beckson M. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion and restraint in an acute inpatient psychiatric setting//J Clin Psychopharmacol, - 2006, 26: 333 - 335.

67. Taylor D., Okocha C., Paton C., et al. Buccal midazolam for agitation on psychiatric intensive care wards//Int J Psychiatry in Clin Prac, 2008, 12: 309 - 311.

68. Lesem M.D., Tran-Johnson T.K., Riesenberg R.A., et al. Rapid acute treatment of agitation in individuals with schizophrenia: Multicenter, randomized, placebo-controlled study of inhaled loxapine//Br J Psychiatry, 2011, 198: 51 - 58.

69. Currier G.W., Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies//J Psychiatr Pract, - 2006; 12 (1): 30 - 40.

70. Villari V., Rocca P., Fonzo V., et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation//Prog Neuropsychopharmacol Biol Psychiatry, - 2008, 32: 405 - 413.

71. Pasin L, Landoni G, Nardelli P, et al. Dexmedetomidine reduces the risk of delirium, agitation and confusion in critically Ill patients: A meta-analysis of randomized controlled trials//J Cardiothorac Vasc Anesth, 2014, 28: 1459 - 1466.

72. Martel M., Sterzinger A., Miner J., et al. Management of acute undifferentiated agitation in the emergency department: A randomized double-blind trial of droperidol, ziprasidone, and midazolam//Acad Emerg Med, 2005,12: 1167 - 1172.

73. Nobay F., Simon B., Levitt A., et al. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients//Acad Emerg Med, 2004, 11: 744 - 749.

74. Taylor D.M., Yap C.Y., Knott J.C., et al. Midazolam-droperidol, droperidol or olanzapine for acute agitation: A randomized clinical trial//Ann Emerg Med, 2017, 69: 318 - 326.

75. Veser F.H., Veser B.D., McMullan J.T., et al. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: A pilot, randomized, double-blind, placebo-controlled trial//J Psychiatr Pract, 2006, 12: 103 - 108.

76. Wilson M.P., MacDonald K., Vilke G.M., et al. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation//J Emerg Med, 2012, 43: 790 - 797.

77. Suzuki H., Takahashi Y. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia//Hum Psychopharmacol, - 2014, N. 29 P. 83 - 88.

78. Meehan K.M., Wang H., David S.R., et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: A double-blind, randomized study in acutely agitated patients with dementia//Neuropsychopharmacology, - 2002, 26: 494 - 504.

79. Ostinelli E.G., Jajawi S., Spyridi S., et al. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)//Cochrane Database Syst Rev, 2018, 1: CD 008074.

80. Zimbroff D.L., Marcus R.N., Manos G., et al. Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole//J Clin Psychopharmacol, 2007, 27: 171 - 176.

81. Ostinelli E.G., Brooke-Powney M.J., Li X., et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)//Cochrane Database Syst Rev, 2017, 7: CD009377.

82. Mantovani C., Labate C.M., Sponholze A.J., et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions//J Clin Psychopharmacol, 2013, 33: 306 - 312.

83. Chouinard G., Annable L., Turnier L., et al. A double-blind randomized clinical trial of rapid tranquillisation with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms//Can J Psychiatry, 1993,38 (Suppl 4): S114 - 121.

84. Knott J.C., Taylor D.M., Castle D.J. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department//Ann Emerg Med, 2006, 47: 61 - 67.

85. Yap C.Y., Taylor D.M., Knott J.C., et al. Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: Subgroup analysis of a randomized controlled trial//Addiction, - 2017, N. 112 P. 1262 - 1269.

86. Мосолов С.Н., Цукарзи Э.Э. Шизофрения//Национальное руководство. Психиатрия под ркд. Александровский Ю.А., Незнанов Н.Г. - Геотар Медиа. - 2018

87. Isbister G., Calver L., Page C., et al. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: The DORM study//Ann Emerg Med, 2010, 56: 392 - 401.

88. Chan E.W., Taylor D.M., Knott J.C., et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: A multicenter, randomized, double-blind, placebo-controlled clinical trial//Ann Emerg Med, 2013, 61: 72 - 81.

89. Scheppke K.A., Braghiroli J., Shalaby M., et al. Prehospital use of IM ketamine for sedation of violent and agitated patients//West J Emerg Med, 2014, 15: 736 - 741.

90. Reade M.C., O"Sullivan K., Bates S., Goldsmith D., Ainslie W.R., Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomized open-label trial//Crit Care. 2009; 13(3): R. 75.

91. Goodwin F.K., Jamison K.R.. Manic-depressive illness. 2nd ed. New York, NY: Oxford University Press; 2007.

92. Yildiz A, Nemeroff C, Ruiz P, (eds). The Bipolar book: history, neurobiology, and treatment.. New York: Oxford University Press; 2015.

93. Goodwin G.M., Haddad P.M., Ferrier I.N., Aronson J.K., Barnes T.R.H., Cipriani A., et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology//J Psychopharma-col. 2016; 30: 495 - 553.

94. Fountoulakis K.N., Kasper S., Andreassen O., Blier P., Okasha A., Severus E., et al. Efficacy of pharmacotherapy in bipolar disorder: report by the WPA section on pharmacopsychiatry//Eur Arch Psychiatry Clin Neurosci. 2012; 262 (Suppl 1): 1 - 48.

95. Selle V, Schalkwijk S, GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics//Pharma-copsychiatry. 2014; 47: 43 - 52.

96. Tondo L, Baldessarini RJ, GH. Options for pharmacological treatment of refractory bipolar depression//Curr Psy-chiatry Rep. 2014; 16: 431 - 8.

97. G, Holtzman J, Tondo L, Baldessarini RJ. Efficacy and tolerability of treatments for bipolar depression//J Affect Disord. 2015; 185: 258 - 62.

98. Fountoulakis K.N., Vieta E., Young A., Yatham L., Grunze H., Blier P., et al. Unmet needs in the treatment of bipolar disorder and recommendations for future research//Int J Neuropsycho-pharmacol. 2017; 20: 196 - 205.

99. Parikh S.V., Kennedy S.H. Integration of Patient, Provider, and Systems Treatment Approaches in Bipolar Disorder: Where Evidence Meets Practice Reality. West Sussex, England: John Wiley & Sons Ltd; 2004.

100. Viktorin A, Lichtenstein P, Thase M.E., et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer//Am J Psychiatry. 2014; 171: 1067 - 73.

101. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)//J Clin Psychiatry. 2010; 71: 163 - 74

102. Peet M. Induction of mania with selective serotonin reuptake inhibi ors and tricyclic antidepressants//Br J Psychiatry. 1994; 164: 549 - 5

103. Blenfet V., Levis S., Dauby J., Beelen L. Pharmacological study of a new tranquilizing agents//Acta Neurol Psychiat (Belgica) 1961;

104. Воловик В.М., Михаленко И.Н., Немчин Т.А. Нейропсихотропные средства в клинике психических и нервных заболеваний. В кн.: Труды ленинградского научно-исследовательского психоневрологического института им. В.М. Бехтерева. Л 1970; 217 - 226.

105. Miskowiak K.W., Carvalho A.F., Vieta E., Kessing L.V. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations//Eur Neuropsychopharmacol. 2016; 26: 1541 - 61

106. Yatham L.N., Mackala S., Basivireddy J., et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomized, open-label, pilot study//Lancet Psychiatry. - 2017. N. 4. P. 208 - 17

107. Reinares M, Sanchez-Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: what, for whom, and when//J Affect Disord. 2014; 156: 46 - 55

108. Maneeton N, Maneeton B, Srisurapanont M, Martin S.D. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012; 12: 160

109. Datto C, Pottorf W.J., Feeley L., LaPorte S., Liss C. Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Ann Gen Psychiatry. 2016; 15: 9.

110. Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature//Can J Psychiatry. - 1995. N. 40. P. 533 - 44.

111. Sachs G.S., Nierenberg A.A., Calabrese J.R.., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression//N Engl J Med. 2007; 356: 1711 - 22.

112. Nemeroff C.B., Evans D.L., Gyulai L., et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression//Am J Psychiatry. 2001; 158: 906 - 12.

113. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials//Br J Psychiatry. 2009; 194: 4 - 9.

114. Calabrese J.R., Bowden C.L., Sachs G.S., et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bi-polar I depression//J Clin Psychiatry. 1999; 60: 79 - 88

115. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study//Am J Psychiatry. 2014; 171: 169 - 77.

116. Fornaro M., Berardis D., Perna G. et al. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews//BioMed Research International//Volume 2017. Article ID 3084859, 17 pages https://doi.org/10.1155/2017/3084859

117. Bond D.J., Lam R.W., Yatham L.N. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis//J Affect Disord. 2010; 124: 228 - 34

118. Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression//Am J Psychiatry. 2016; 173: 271 - 81

119. Yatham L.N., Vieta E., Durgam S., et al. Efficacy of Cariprazine in Bipolar Depression: Post Hoc Band-Pass Analyses of 2 Randomized, Double-Blind, Placebo-Controlled Trials. Atlanta, Georga: American Psychiatric Association Annual meeting; 2016

120. Earley W., Burgess M., Rekeda L. et al. Cariprazine in treatment of bipolar disorder. Double blind. placebo-controlled phase 3 study//Am J Psychiatry. - 2019. - N 176. - p. 439 - 448.

121. Ушкалова А.В., Костюкова Е.Г., Мосолов С.Н. Проблемы диагностики и терапии биполярной депрессии: от доказательных научных исследований к клиническим рекомендациям.//Биологические методы терапии психических расстройств (доказательная медицина-клинической практике) под. редакцией С.Н. Мосолова. Москва, 2012. Стр 491 - 529

122. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, et al. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis.//J Affect Disord. 2010. - N 122. - p. 1 - 9

123. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study.//J Affect Disord, 2005. - vol. 85. - N 3. - p. 259 - 660

124. Calabrese P. et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.//J Clin Psychiatry. - 1999. - N 60. - p. 79 - 88

125. Ballenger J.C. The clinical use of carbamazepine in affective disorders.//J Clin Psychiatry 1988. - N 49. - p. 13 - 21

126. Post R.M. et al. Alternative approaches to refractory depression in bipolar illness.//Depress Anxiety. - 1997. - N 5. - p. 175 - 189

127. Grunze H., Vieta E., Goodwin G.M., Bowden C, Licht RW, HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.//World J Biol Psychiatry. - 2010. - N 11. - p. 81 - 109

128. McGirr A, Vohringer P.A., Ghaemi S.N., Lam R.W., Yatham L.N. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabilizer or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomized placebo-controlled trials//Lancet Psychiatry. 2016; 3: 1138 - 46

129. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression//Arch Gen Psychiatry. 2003; 60: 1079 - 88.

130. Brown E.B., McElroy S.L., Keck P.E. Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression//J Clin Psychiatry. 2006; 67: 1025 - 33

131. Schoeyen H.K., Kessler U., Andreassen O.A., et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment//Am J Psychiatry. 2015; 172: 41 - 51

132. Dunn R.T., Stan V.A., Chriki L.S., Filkowski M.M., Ghaemi S.N. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression//J Affect Disord. 2008; 110: 70 - 4

133. McElroy S.L., Suppes T., Frye M.A., et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial//J Affect Disord. 2007; 101: 275 - 81

134. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression//J Clin Psychiatry. 2012; 73: 81 - 6

135. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials//PLoS ONE. 2014; 9: e96905.

136. Rosenblat J.D., Kakar R., Berk M., et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis//Bipolar Disord. 2016; 18: 89 - 101

137. Hines M., Blum J. J. Bend propagation in flagella. II. Incorporation of dynein cross-bridge kinetics into the equations of motion//Biophysical journal. - 1979. - T. 25. - N. 3. - С. 421 - 441.

138. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepally H, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42 - 53.

139. Tseng P.T., Chen Y.W., Tu K.Y., et al. Light therapy in the treatment of patients with bipolar depression: a meta-analytic study//Eur Neuropsychopharmacol. 2016; 26: 1037 - 47

140. Bauer M, Berman S, Stamm T, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study//Mol Psychiatry. 2016; 21: 229 - 36

141. Berk M, Copolov D.L., Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - A double-blind randomized placebo-controlled trial//Biol Psychiat. 2008; 64: 468 - 75

142. McGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression//World Psychiatry. 2016; 15: 85 - 6

143. Post R.M., Altshuler L.L., Leverich G.S., et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline//Br J Psychiatry. 2006; 189: 124 - 31

144. Himmelhoch J.M., Fuchs C.Z., Symons B.J. A double-blind-study of tranylcypromine treatment of major anergic depression//J Nerv MentDis. 1982; 170: 628 - 34

145. Himmelhoch J.M., Thase M.E., Mallinger A.G., Houck P. Tranylcypromine versus imipramine in anergic bipolar depression//Am J Psychiatry. 1991; 148: 910 - 6

146. Gijsman H. J. et al. Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials.//Am J Psychiatry. - 2004. - N 161. - p. 1537 - 1547

147. Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62: 464 - 8.

148. Calabrese JR, Keck PE, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340 - 2.

149. Young A.H., Calabrese J.R., Gustafsson U., et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies//Int J Bipolar Disord. 2013; 1: 10

150. Calabrese J.R., Keck P.E., Macfadden W., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression//Am J Psychiatry. 2005; 162: 1351 - 60

151. Thase M.E., Macfadden W., Weisler R.H., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression - A double-blind, placebo-controlled study (The BOLDER II study)//J Clin Psychopharmacol. 2006; 26: 600 - 9

152. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression//J Affect Disord. 2010; 121: 106 - 15

153. Young A.H., McElroy S.L., Bauer M., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)//J Clin Psychiatry. 2010; 71: 150 - 62

154. Jeong J.H., Bahk W.M., Woo Y.S., et al. Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study//Neuropsychiatr Dis Treat. 2013; 9: 197 - 204

155. Ahn Y.M., Nam J.Y., Culver J.L., Marsh W.K., Bonner J.C., Ketter T.A. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression//Ann Clin Psychiatry. 2011; 23: 17 - 24

156. Judd L.L., Akiskal H.S., Schettler P.J., et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder//Arch Gen Psychiatry. 2003; 60: 261 - 9

157. Suppes T, Marangell L.B., Bernstein I.H., et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression//J Affect Disord. 2008; 111: 334 - 43

158. Donnelly E.F., Goodwin F.K., Waldman I.N., Murphy D.L. Prediction of antidepressant responses to lithium//Am J Psychiatry. 1978; 135: 552 - 6

159. Baron M, Gershon E.S., Rudy V., Jonas W.Z., Buchsbaum M. Lithium-carbonate response in depression - prediction by unipolar bipolar illness, average-evoked response, catechol-o-methyl transferase, and family history//Arch Gen Psychiatry. 1975; 32: 1107 - 11

160. Amsterdam J.D., Lorenzo-Luaces L., Soeller I., Li S.Q., Mao J.J., DeRubeis R.J. Short-term venlafaxine vs. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate//Br J Psychiatry. 2016; 208: 359 - 65

161. Calabrese J.R., Huffman R.F., White R.L., et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials//Bipolar Disord. 2008; 10: 323 - 33

162. Altshuler L.L., Sugar C.A., McElroy S.L., et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison//Am J Psychiatry 2017; 173: 266 - 76

163. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode//J Clin Psychopharmacol. 1998; 18: 414 - 7

164. Amsterdam J.D., Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression//J Affect Disord. 2000;59: 225 - 9

165. Calabrese J.R., Bowden C.L., Sachs G., et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder//J Clin Psychiatry. 2003; 64: 1013 - 24

166. Sachs G.S. A 25-year-old woman with bipolar disorder//JAMA. 2001; 285: 454 - 62

167. Muzina D.J., Gao K., Kemp D.E., et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial//J Clin Psychiatry. 2011; 72: 813 - 9

168. Young L.T., Joffe R.T., Robb J.C., MacQueen G.M., Marriott M., Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression//Am J Psychiatry. 2000; 157: 124 - 6

169. Winsberg M.E., DeGolia S.G., Strong C.M., Ketter T.A. Divalproex therapy in medicatiIon-naive and mood-staIbilizer-naive bipolar II depression//J Affect Disord. 2001; 67: 207 - 12

170. Wang P.W., Nowakowska C., Chandler R.A., et al. Divalproex extended-release in acute bipolar II depression//J Affect Disord. 2010; 124: 170 - 3

171. Frankenburg F.R., Zanarini M.C. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study//J Clin Psychiatry. 2002; 63: 442 - 6

172. Amsterdam J.D., Shults J., Brunswick D.J., Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate//Bipolar Disord. 2004; 6: 75 - 81.

173. Amsterdam J.D., Garcia-Espana F., Fawcett J., et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode//J ClinPsychopharmacol. 1998; 18: 435 - 40

174. Amsterdam J.D., Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study//Am J Psychiatry. 2010; 167: 792 - 800.

175. Fornaro M, McCarthy M.J., De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study//Neuropsychiatr Dis Treat. 2013; 9: 243 - 51

176. Magalhaes P.V., Dean O.M., Bush A.I., et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial//J Affect Disord. 2011; 129: 317 - 20

177. Zarate C.A., Payne J.L., Singh J., et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study//Biol Psychiat. 2004; 56: 54 - 60

178. Stamm T.J., Lewitzka U., Sauer C., et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study//J Clin Psychiatry. 2014; 75: 162 - 8

179. McIntyre R.S., Suppes T., Tandon R., et al. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder//J Clin Psychiatry. 2017; 78(6): 703 - 713

180. Patkar A, Gilmer W, Pae CU, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state//PLoS ONE. 2012; 7: e34757

181. Liebowitz M.R., Salman E., Mech A., et al. Ziprasidone monotherapy in bipolar II depression: an open trial//J Affect Disord. 2009; 118: 205

182. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. 2009. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis//J Clin Psychiatry. 70: 1424 - 1431

183. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression//Arch Gen Psychiatry. 60: 1079 - 1088

184. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC. 2012. Randomized, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression//Br J Psychiatry. 201: 376 - 382

185. Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. 2014. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features//J Affect Disord. 164: 57 - 62.

186. Dilsalver S. 1996. Treatment of bipolar depression with carbamazepine: Results of an open study//Biological Psychiatry 40(9): 935 - 7

187. McIntyre R.S., Cucchiaro J., Pikalov A., Kroger H., Loebel A. 2015. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial//J Clin Psychiatry. 76: 398 - 405

188. Palma M, Ferreira B, Borja-Santos N, Trancas B, Monteiro C, Cardoso G. 2016. Efficacy of electroconvulsive therapy in bipolar disorder with mixed features//Depress Res Treat. 2016: 8306071.

189. Medda P, Toni C, Mariani MG, De Simone L, Mauri M, Perugi G. 2015. Electroconvulsive therapy in 197 patients with a severe, drug-resistant bipolar mixed state: treatment out-come and predictors of response//J Clin Psychiatry. 76: 1168 - 1173

190. Perugi G, Medda P, Reis J, Rizzato S, Giorgi MM, Mauri M. 2013. Clinical subtypes of severe bipolar mixed states//J Affect Disord. 151: 1076 - 1082

191. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group//Am J Psychiatry. - 1999. N. 156 P. 702 - 709

192. Baldessarini R.J., Hennen J., Wilson M., Calabrese J., Chengappa R., Keck P.E. Jr, McElroy S.L., Sachs G., Vieta E., Welge J.A., et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups//J Clin Psychopharmacol. - 2003. N. 23 P. 370 - 376.

193. Baker R.W., Tohen M., Fawcett J., Risser R.C., Schuh L.M., Brown E., Stauffer V.L., Shao L., Tollefson G.D. Acute dysphoric mania: treatment response to olanzapine versus placebo//J Clin Psychopharmacol. - 2003. N. 23 P. 132 - 137

194. Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. 2012. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study//J Affect Disord. 136: 476 - 484.

195. Keck P.E., Versiani M, Potkin S, West S.A., Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial//Am J Psychiatry. - 2003. N. 160. P. 741 - 748.

196. Stahl S, Lombardo I, Loebel A, Mandel FS. 2010. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies//J Affect Disord. 122: 39 - 45.

197. Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy//Arch Gen Psychiatry. - 2002. N. 59 P. 62 - 69

198. Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania//Br J Psychiatry. - 2004. 185: 472 - 478

199. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study//J Clin Psychiatry. - 2009. 70: 1540 - 1547.

200. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania//Am J Psychiatry. - 2003. 160: 1651 - 1658

201. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study//J Psychopharmacol (Oxford). - 2006. 20: 536 - 546.

202. Suppes T, Eudicone J, McQuade R, Pikalov A, III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder//J Affect Disord. - 2008. 107: 145 - 154

203. Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder//Bipolar Disord. - 2010. 12: 230 - 243

204. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study//J Affect Disord. - 2012. 136: e51 - e60.

205. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study//J Affect Disord. - 2011. 129: 252 - 260

206. Suppes T, Ketter TA, Gwizdowski IS, Dennehy EB, Hill SJ, Fischer EG, Snow DE, Gonzalez R, Sureddi S, Shivakumar G, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo//J Affect Disord. - 2013. 150: 37 - 43

207. Iosse G, Lavuane M. Le Tartrate d'alimemazine in ambulatory psychiatric practice. Gasette Med (France) 1961; 2: 193

208. Calabrese JR, Keck PE, Jr., Starace A, Lu K, Ruth A, Laszlovszky I, Nemeth G, Durgam S. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study//J Clin Psychiatry. - 2015. 76: 284 - 292.

209. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial//Bipolar Disord. - 2015. 17: 63 - 75.

210. Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Nemeth G, Durgam S. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial//J Affect Disord. - 2015. 174: 296 - 302.

211. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials//Eur Neuropsychopharmacol. - 2015. 25: 1882 - 1891.

212. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania//Biol Psychiatry. - 1992. 32: 270 - 280

213. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania//J Child Adolesc Psychopharmacol. - 2002. 12: 93 - 99

214. Mokhber N, Lane CJ, Azarpazhooh MR, Salari E, Fayazi R, Shakeri MT, Young AH. Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran//Neuropsychiatr Dis Treat. - 2008. 4: 227 - 234

215. McElroy SL, Soutullo CA, Keck PE, Jr, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder//Ann-Clin Psychiatry. - 1997. 9: 99 - 103.

216. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell"Osso L, Cassano GB. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode//J Affect Disord. - 2004. 79: 273 - 277.

217. Perlis RH, Baker RW, Zarate CA Jr, Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial//J Clin Psychiatry. - 2006. 67: 1747 - 1753.

218. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania//Arch Gen Psychiatry. - 2003. 60: 1218 - 1226.

219. Shorter D, Healy D. Shock therapy: a history of electroconvulsive therapy in mental illness//London (UK): Rutgers-University Press - 2007.

220. Stromgren LS. Electroconvulsive therapy in Aarhus, Denmark, in 1984: it's application in nondepressive disorders//Convuls Ther. - 1988. 4: 306 - 313.

221. Valenti M, Benabarre A, Garcia-Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder//Eur Psychiatry. - 2008. 23: 53 - 56.

222. Gruber NP, Dilsaver SC, Shoaib AM, Swann AC. ECT in mixed affective states: a case series//J ECT. - 2000. 16: 183 - 188.

223. Devanand DP, Polanco P, Cruz R, Shah S, Paykina N, Singh K, Majors L. The efficacy of ECT in mixed affective states//J ECT. - 2000. 16: 32 - 37.

224. Barzman DH, DelBello MP, Kowatch RA, Warner J, Rofey D, Stanford K, Rappaport K, Daniels JP, Strakowski SM. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders//J Child Adolesc-Psychopharmacol. - 2005. 15: 931 - 937.

225. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission//Arch Gen Psychiatry. - 2003. 60: 402 - 407

226. Sanchez-Moreno J, Martinez-Aran A, Vieta E. Treatment of Functional Impairment in Patients with Bipolar Disorder//Current psychiatry reports. 2017; 19(1): 3.

227. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders//Nat Rev Dis Primers. 2018; 4: 18008.

228. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder//Bipolar disorders. 2004; 6(6): 504 - 518.

229. Костюкова Е.Г., Мосолов С.Н. Обзор рандомизированных контролируемых исследований атипичных антипсихотиков при длительной противорецидивной терапии биполярного аффективного расстройства//Современная терапия психических расстройств. - 2013. - No 1. - С. 2 - 11

230. Костюкова Е.Г., Раюшкин В.А., Ушаков Ю.В. Профилактика рецидивов аффективного и шизоаффективного психоза с помощью карбамазепина (мет. рек. под научн. рук. Г.П. Пантелеевой). - М., 1991; 29.

231. Denicoff K.D., Smith-Jackson E.E., Disney E.R., Ali S.O., Leverich G.S., Post R.M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder//J Clin Psychiatry. - 1997. - Vol. 58. - P. 470 - 478

232. Post RM. Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention. Bipolar disorders. 2016; 18(4): 315 - 324

233. Мосолов С.Н. Клиника и терапия затяжных (стационарных и лабильно-континуальных) форм фазнопротекающих психозов (клинико-экспериментальное исследование): дис. ... д-ра мед. наук. - М., 1992. - Т. 2. - С. 307 - 322

234. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry. - 2002. - Vol. 159. - 4 suppl. - P. 1 - 50

235. Diagnosing, assessing and managing bipolar disorder in adults in secondary care. Nice, 2015. http://pathways.nice.org.uk/pathways/bipolar-disorder

236. Riemann D, Gann H, Hohagen F, Bahro M, Muller WE, Berger M. The effect of carbamazepine on endocrine and sleep EEG variables in a patient with 48-hour rapid cycling, and healthy controls//Neuropsychobiology - 1993. 27: 163 - 170

237. Vanelle JM, Loo H, Galinowski A, de Carvalho W, Bourdel MC, Brochier P, Bouvet O, Brochier T, Olie JP. Maintenance ECT in intractable manic-depressive disorders//Convuls Ther. - 1994. 10: 195 - 20

238. Edmonds LD, Oakley GP: Ebstein's anomaly and maternal lithium exposure during pregnancy.//Teratology, 1990, N 41, p. 551 - 552

239. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicenter study of pregnancy outcome after lithium exposure during first trimester//Lancet, 1992, N 339, p. 530 - 533

240. American Academy of Pediatrics. Use of Psychoactive Medication During Pregnancy and Possible Effects on the Fetus and Newborn (RE9866).//Arch Pediatr Adolesc Med, 2002, vol156, p. 1129 - 32

241. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period.//Am J Psychiatry, 2004, N 161, p. 608 - 20

242. Schou M, Amdisen A, Steenstrup OR: Lithium and pregnancy, II: hazards to women given lithium during pregnancy and delivery//Br Med J, 1973, vol. 2, p. 137 - 138

243. Okuma T. et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness//Psychopharmacology. - 1981. - Т. 73. - N. 1. - С. 95 - 96.

244. Weinstein MR: Lithium treatment of women during pregnancy and in the post-delivery period, in Handbook of Lithium Therapy. Edited by Johnson FN. Baltimore, University Park Press, 1980, p. 421 - 429

245. Iqbal MM, Gundlapalli SP, Ryan WG, et al. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.//South Med J, 2001, p. 94:304

246. Pinelli JM, Symington AJ, Cunningham KA, Paes BA. Case report and review of the perinatal implications of maternal lithium use.//Am J Obstet Gynecol, 2002, N 187, p. 245

247. Tomson T. Which Drug for the Pregnant Woman with Epilepsy?//NEJM, 2009, 360, p. 1667 - 1669

248. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.//Acta Paediatr., 2004, 93(2), p. 174 - 176

249. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.//J Neurol Neurosurg Psychiatry., 2006, N 77(2), p. 193 - 198.

250. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.//N Engl J Med, 2009, N 360, p. 1597

251. Ward S, Wisner L. Collaborative Management of Women with Bipolar Disorder During Pregnancy and Postpartum: Pharmacologic Considerations.//J Midwifery Womens Health, 2007, 52(1), p. 3 - 13

252. Prakash, Prabhu L V, Nasar M A, Rai R, Madhyastha S, Singh G Lamotrigine in pregnancy: safety profile and the risk of malformations.//Singapore Med J, 2007, vol. 48, N 10, p. 880 - 883

253. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs.//Expert Rev Neurother., 2010, Jun, N 10(6), p. 943 - 959

254. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs.//Neurology, 1992, N 42, p. 111

255. Galbally M, Roberts M, Buist A. Perinatal Psychotropic Review Group. Mood stabilizers in pregnancy: a systematic review//Aust N Z J Psychiatry., 2010, Nov; N 44(11), p. 967 - 77

256. NICE clinical guideline 38 Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care, July, 2006

257. NICE clinical guideline 45. Antenatal and postnatal mental health: clinical management and service guidance. April, 2007

258. APA. Practice guideline for the treatment of patients with bipolar disorder (revision).//Am J Psy 2002, N 159, p. 1 - 50

259. Цукарзи Э.Э. Суицид: оценка рисков и первая помощь. Определение уровня суицидального риска с помощью Колумбийской Шкалы Оценки Тяжести Суицида (C-SSRS)//Современная терапия психических расстройств. - 2011. - Вып. 2. - С. 30 - 39.

260. Kilbourne A. M. et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder//Journal of affective disorders. - 2007. - Т. 102. - N. 1 - 3. - С. 145 - 151.

261. Garcia-Portilla M. P. et al. The prevalence of metabolic syndrome in patients with bipolar disorder//Journal of affective disorders. - 2008. - Т. 106. - N. 1 - 2. - С. 197 - 201.

262. U., Can Tuman T., O. Increased neutrophil/lymphoctye ratio in patients with bipolar disorder: a preliminary study//Psychiatria Danubina. - 2015. - Т. 27. - N. 2. - С. 0 - 184.

263. Salvi V. et al. Metabolic syndrome in Italian patients with bipolar disorder//General hospital psychiatry. - 2008. - Т. 30. - N. 4. - С. 318 - 323.

264. Zarate C. A., Tohen M., Zarate S. B. Thyroid function tests in first-episode bipolar disorder manic and mixed types//Biological psychiatry. - 1997. - Т. 42. - N. 4. - С. 302 - 304.

265. Chang K. D. et al. Differences in thyroid function between bipolar manic and mixed states//Biological psychiatry. - 1998. - Т. 43. - N. 10. - С. 730 - 733.

266. Rolstad S. et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls//PLoS One. - 2015. - Т. 10. - N. 5. - С. e0127100.

267. Fusar-Poli L. et al. Gender differences in complete blood count and inflammatory ratios among patients with bipolar disorder//Brain Sciences. - 2021. - Т. 11. - N. 3. - С. 363.

268. E. et al. Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder//Acta Psychiatrica Scandinavica. - 2016. - Т. 133. - N. 4. - С. 266 - 276.

269. Инструкция по медицинскому применению лекарственного препарата - окскарбазепин//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=37fbab30-b700-488b-84c8-6ffabd375630&t=

270. Инструкция по медицинскому применению лекарственного препарата топирамат//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d5eddaa0-1a60-4360-bf1c-68ccc63f9b73&t=

271. Инструкция по медицинскому применению лекарственного препарата габапентин//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fd656541-0329-4503-96b1-df1135ac2932&t=

272. Инструкция по медицинскому применению лекарственного препарата лоразепам//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=63dcb296-9fae-434e-b54d-8c28052c77fa&t=

273. Инструкция по медицинскому применению лекарственного препарата мидазолам//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a5bf3301-57b9-4e1c-94de-d30fc2193dbe&t=

274. Инструкция по медицинскому применению лекарственного препарата клоназепам//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=604b738d-6627-4703-a294-b278ff0e14d5&t= Yatham L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder//Bipolar disorders. - 2018. - Т. 20. - N. 2. - С. 97 - 170.

275. L. et al. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone//Brazilian Journal of Psychiatry. - 2011. - Т. 33. - N. 1. - С. 30 - 39.

276. Rund D. A. et al. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department//The Journal of emergency medicine. - 2006. - Т. 31. - N. 3. - С. 317 - 324.

277. Инструкция по медицинскому применению лекарственного препарата прометазин//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1e2bb187-731d-4f18-ac61-7214cacd8b11&t=

278. Vraylar (cariprazine) dosing, indications, interactions//https://reference.medscape.com/drug/vraylar-cariprazine-999874

279. Инструкция по медицинскому применению лекарственного препарата лития карбонат//http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ad21f5-52ae-4d91-811f-eac4416e4036&t=

280. (olanzapine) Full prescribing information//https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020592s062021086s040021253s048lbl.pdf

281. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial//Acta Psychiatrica Scandinavica. - 2001. - Т. 104. - N. 2. - С. 104 - 109.

282. Bowden C. L. et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial//The Journal of clinical psychiatry. - 2010. - Т. 71. - N. 2. - С. 130 - 137.

283. Bozikas V. P. et al. Treatment of acute mania with topiramate in hospitalized patients//Progress in Neuro-Psychopharmacology and Biological Psychiatry. - 2002. - Т. 26. - N. 6. - С. 1203 - 1206.

284. Chengappa K. N. R., Gershon S., Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder//Bipolar disorders. - 2001. - Т. 3. - N. 5. - С. 215 - 232.

285. Ifteni P. et al. Rapid clozapine titration in treatment-refractory bipolar disorder//Journal of affective disorders. - 2014. - Т. 166. - С. 168 - 172.

286. Li X. B. et al. Clozapine for treatment resistant bipolar disorder: a systematic review//Bipolar disorders. - 2015. - Т. 17. - N. 3. - С. 235 - 247.

287. Bradwejn J. et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania//Journal of clinical psychopharmacology. - 1990.

288. Currier G. W. et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam//Journal of Clinical Psychiatry. - 2004. - Т. 65. - N. 3. - С. 386 - 394.

289. Bieniek S. A. et al. A double blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation//Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. - 1998. - Т. 18. - N. 1. - С. 57 - 62.

290. Yatham L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder//Bipolar disorders. - 2018. - Т. 20. - N. 2. - С. 97 - 170.

291. Beach, S. R., Gross, A. F., Hartney, K. E., Taylor, J. B., & Rundell, J. R. (2020). Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use. General Hospital Psychiatry. doi: 10.1016/j.genhosppsych.2020.08.008

292. Bigal, M. E., Bordini, C. A., & Speciali, J. G. (2002). Intravenous chlorpromazine in the Emergency Department treatment of migraines: a randomized controlled trial. The Journal of Emergency Medicine, 23(2), 141 - 148. doi: 10.1016/s0736-4679(02)00502-4

293. Huf G. et al. Haloperidol plus promethazine for psychosis induced aggression//Cochrane Database of Systematic Reviews. - 2016. - N. 11.

294. Young A. H. et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)//The Journal of clinical psychiatry. - 2010. - Т. 71. - N. 2. - С. 150 - 162.

295. Goodwin F. K., Murphy D. L., Bunney W. E. Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study//Archives of general psychiatry. - 1969. - Т. 21. - N. 4. - С. 486 - 496.

296. Amsterdam J. D., Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression - lack of manic induction//Journal of affective disorders. - 2005. - Т. 87. - N. 1. - С. 121 - 130.

297. Anmella G. et al. Expert advice on the management of valproate in women with bipolar disorder at childbearing age//European Neuropsychopharmacology. - 2019. - Т. 29. - N. 11. - С. 1199 - 1212.

298. Mosolov S., Born C., Grunze H. Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States.//Medicina. - 2021. - Т. 57. - N 624. - С. 1 - 17. https://doi.org/10.3390/medicina57060624

299. Pina L.S., Bouckaert, F., Obbels J. et al. Maintenance Electroconvulsive Therapy in Severe Bipolar Disorder A Retrospective Chart Review.//J. ECT. - 2016. - Т. 32. - С. 23 - 28.

300. Hausmann A., Post T., Post F, et al. Efficacy of Continuation/Maintenance Electroconvulsive Therapy in the Treatment of Patients with Mood Disorders A Retrospective Analysis.//J. ECT. - 2019. - N 35. - С. 122 - 126.

301. Mosolov S.N., Yaltonskaya P.A., Senko O.V., Angst J. Validation of the Russian version of the hypomania checklist (HCL-33) for the detection of bipolar disorder in patients with a current diagnosis of recurrent depression//Journal of Affective Disorders Reports, 2021; Vol. 4, p. 1 - 7 (100086) https://doi.org/10.1016/j.jadr.2021.100086

302. Berk M. et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial//Biological psychiatry. - 2008. - Т. 64. - N. 6. - С. 468 - 475.

303. Patel M.X., Sethi F.N., Barnes T.R. et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation.//Journal of Psychopharmacology. - 2018. - Т. 32. - N 6. - С. 601 - 40. http://dx.doi.org/10.1177/0269881118776738

304. Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: Consensus statement of the American Association for Emergency Psychiatry Project Beta psychopharmacology work-group.//West J Emerg Med. - 2012. - Т. 13. - С. 26 - 34.

305. TREC Collaborative Group. Rapid tranquillisation for agitated patients in psychiatric rooms: A randomised trial of midazolam versus haloperidol plus promethazine.//BMJ. - 2003. - N 327. - С. 708 - 713.

306. Calver L, Drinkwater V, Isbister GK. A prospective study of high dose sedation for rapid tranquillisation of acute behavioural disturbance in an acute mental health unit.//BMC Psychiatry. - 2013. - Т. 13. - С. 225.